Edwards Lifesciences (EW) PT Raised to $100 at Stifel

Stifel analyst Rick Wise raised the price target on Edwards Lifesciences (NYSE: EW) to $100.00 (from $95.00) while maintaining a Buy rating.

The analyst comments "Today, we attended Edwards annual investor day meeting in Irvine, California. The wide-ranging event highlighted the company’s broad-based, truly-impressive innovation, strong leadership, and offered a constructive initial 2026 guidance “starting point”. Our bottom line: We left the meeting feeling positive about Edwards 2026 outlook and long-term set-up. The initial 8-10% Edwards 2026 revenue growth guidance, versus our prior 9.4% projection, looks achievable and potentially leaves room for upside as multiple regulatory catalysts and new product launch timing plays-out. Overall, to us, the 2026 guidance included no significant negative or positive surprises when compared to our and Consensus projections. With 2025 guidance re-affirmed, we very slightly tweaked our 2026 numbers (see Exhibit 3). Longer-term, we were especially encouraged by Edwards' clearly evident and rapid innovation cadence. In both the TAVR (74% of 2025E sales) and TMTT (9% of 2025E sales) business lines, management highlighted multiple next-generation products, including: (1) the Sapien X4 TAVR device, where clinical work is still ongoing but could finish next-year; (2) PASCAL for mitral disease, where the company has already launched its fourth generation product; and (3) a next-generation EVOQUE tricuspid valve replacement system is expected 2H27. As well, the year-ahead also includes several potential growth enhancing catalysts...Sapien M3 Mitral valve replacement system approval early in the year, two-year EVOQUE tricuspid valve replacement data in 2Q26, TAVR PROGRESS moderate aortic stenosis data at TCT, CLASP II TR tricuspid valve repair data at TCT."

You May Also Be Interested In

• Marvell (MRVL) PT Raised to $325 at Oppenheimer
• Rubrik Inc (RBRK) PT Raised to $114 at Piper Sandler
• Build-A-Bear Workshop (BBW) PT Lowered to $37 at DA Davidson Following Q2 Miss